The FDA removed the warning requirement in 2003, as it had "conducted a scientific review of several post-market studies submitted by P&G, as well as adverse event reports submitted by P&G and the Center for Science in the Public Interest. The FDA concluded the label statement was no longer warranted". The FDA also agreed with P&G that the "label statement could be misleading and cause consumers of olestra to attribute serious problems to olestra when this unlikely to be the case".